These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 22396259

  • 1. Exfoliative esophagitis and esophageal ulcer induced by dabigatran.
    Okada M, Okada K.
    Endoscopy; 2012; 44 Suppl 2 UCTN():E23-4. PubMed ID: 22396259
    [No Abstract] [Full Text] [Related]

  • 2. [Exfoliative esophagitis while taking dabigatran].
    Scheppach W, Meesmann M.
    Dtsch Med Wochenschr; 2015 Apr; 140(7):515-8. PubMed ID: 25826037
    [Abstract] [Full Text] [Related]

  • 3. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE, Lake JD.
    Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597
    [No Abstract] [Full Text] [Related]

  • 4. Dabigatran-induced esophagitis.
    Ootani A, Hayashi Y, Miyagi Y.
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):e55-6. PubMed ID: 24036049
    [No Abstract] [Full Text] [Related]

  • 5. Dabigatran in patients with nonvalvular atrial fibrillation.
    Gage L.
    J Am Coll Cardiol; 2011 Jul 26; 58(5):551; author reply 551. PubMed ID: 21777759
    [No Abstract] [Full Text] [Related]

  • 6. Extensive dabigatran-induced exfoliative esophagitis harboring squamous cell carcinoma.
    Zimmer V, Casper M, Lammert F.
    Endoscopy; 2014 Jul 26; 46 Suppl 1 UCTN():E273-4. PubMed ID: 24906097
    [No Abstract] [Full Text] [Related]

  • 7. Place of dabigatran in contemporary pharmacotherapy.
    Gums JG.
    Pharmacotherapy; 2011 Apr 26; 31(4):335-7. PubMed ID: 21449622
    [No Abstract] [Full Text] [Related]

  • 8. [New anticoagulants: "efficacy and safety" or "efficacy or safety"].
    Pernod G.
    J Mal Vasc; 2011 Dec 26; 36(6):337-8. PubMed ID: 21907510
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV, Gage BF.
    Circulation; 2011 Jun 07; 123(22):2562-70. PubMed ID: 21606397
    [Abstract] [Full Text] [Related]

  • 10. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 11. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 31; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 12. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
    Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ.
    Circulation; 2011 Jan 18; 123(2):131-6. PubMed ID: 21200007
    [Abstract] [Full Text] [Related]

  • 13. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
    Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C, Italian Federation of Thrombosis Centers.
    Thromb Haemost; 2011 Nov 18; 106(5):868-76. PubMed ID: 21946939
    [Abstract] [Full Text] [Related]

  • 14. [Wünderlich syndrome in patient anticoagulated with dabigatran].
    de Gea-García JH, Alvarez M, Ruiz-Villa G, Jiménez-Parra JD.
    Med Clin (Barc); 2013 Aug 17; 141(4):184-5. PubMed ID: 23369498
    [No Abstract] [Full Text] [Related]

  • 15. Next generation anticoagulants may push warfarin to the wayside.
    Kirsch B.
    Manag Care; 2011 Feb 17; 20(2):33-6. PubMed ID: 21428128
    [No Abstract] [Full Text] [Related]

  • 16. The use of dabigatran immediately after atrial fibrillation ablation.
    Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.
    J Cardiovasc Electrophysiol; 2012 Mar 17; 23(3):264-8. PubMed ID: 21955008
    [Abstract] [Full Text] [Related]

  • 17. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.
    Circulation; 2012 Feb 07; 125(5):669-76. PubMed ID: 22215856
    [Abstract] [Full Text] [Related]

  • 18. [Atrial fibrillation: what the GP needs to know].
    Diener HC, Kaeufer T, Bode C.
    MMW Fortschr Med; 2011 Sep 22; 153(38):44-7; quiz 48. PubMed ID: 21977796
    [No Abstract] [Full Text] [Related]

  • 19. Thrombotic events after discontinuing dabigatran: rebound or resumption?
    Thorne KM, Dee S, Jayathissa S.
    BMJ; 2012 Jul 03; 345():e4469. PubMed ID: 22761096
    [No Abstract] [Full Text] [Related]

  • 20. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
    Wychowski MK, Kouides PA.
    Ann Pharmacother; 2012 Apr 03; 46(4):e10. PubMed ID: 22496474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.